{"id":55498,"date":"2026-01-26T20:34:29","date_gmt":"2026-01-26T12:34:29","guid":{"rendered":"https:\/\/flcube.com\/?p=55498"},"modified":"2026-01-26T20:34:31","modified_gmt":"2026-01-26T12:34:31","slug":"healzen-inks-global-dac-partnership-second-tpd-deal-following-jj-alliance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55498","title":{"rendered":"HealZen Inks Global DAC Partnership, Second TPD Deal Following J&amp;J Alliance"},"content":{"rendered":"\n<p><strong>Hangzhou HealZen Therapeutics Co., Ltd.<\/strong> announced a <strong>global partnership<\/strong> with an <strong>undisclosed American biotechnology company<\/strong> for <strong>degrader\u2011antibody conjugates (DACs)<\/strong>, retaining <strong>Greater China rights<\/strong> while securing <strong>upfront payments, milestones, royalties, and sublicensing revenue<\/strong>. The transaction marks HealZen\u2019s <strong>second overseas licensing deal<\/strong> in <strong>targeted protein degradation (TPD)<\/strong>, following its <strong>BTK degrader agreement with Johnson &amp; Johnson<\/strong> in early\u202f2025.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure\">Deal Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Hangzhou HealZen Therapeutics (China) and undisclosed US biotech<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>Degrader\u2011antibody conjugates (DACs)<\/td><\/tr><tr><td><strong>Therapeutic Area<\/strong><\/td><td>Targeted protein degradation (TPD)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Global (HealZen retains Greater China rights)<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Upfront payment + development milestones + sales royalties + sublicensing revenue<\/td><\/tr><tr><td><strong>Deal Significance<\/strong><\/td><td>Second TPD partnership for HealZen (following J&amp;J BTK degrader deal, Q1\u202f2025)<\/td><\/tr><tr><td><strong>Status<\/strong><\/td><td>Agreement executed; undisclosed partner to lead ex\u2011China development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile-degrader-antibody-conjugates-dacs\">Technology Profile: Degrader\u2011Antibody Conjugates (DACs)<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Combines <strong>antibody targeting precision<\/strong> with <strong>protein degradation technology<\/strong>, delivering <strong>PROTACs or molecular glues<\/strong> directly to tumor cells while sparing healthy tissue<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Overcomes <strong>systemic toxicity<\/strong> and <strong>poor bioavailability<\/strong> challenges of oral degraders by leveraging <strong>antibody\u2011mediated delivery<\/strong><\/li>\n\n\n\n<li><strong>TPD Platform:<\/strong> HealZen\u2019s proprietary <strong>targeted protein degradation<\/strong> capabilities enable <strong>selective destruction<\/strong> of disease\u2011causing proteins previously considered \u201cundruggable\u201d<\/li>\n\n\n\n<li><strong>Clinical Potential:<\/strong> DACs represent <strong>next\u2011generation oncology therapeutics<\/strong> with <strong>improved therapeutic indices<\/strong> vs. traditional antibody\u2011drug conjugates (ADCs)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China<\/th><th>Global<\/th><\/tr><\/thead><tbody><tr><td><strong>TPD Market (2030E)<\/strong><\/td><td>\u00a528\u202fbillion<\/td><td>$18\u202fbillion<\/td><\/tr><tr><td><strong>DAC Segment Penetration<\/strong><\/td><td>&lt;1\u202f%<\/td><td>&lt;2\u202f%<\/td><\/tr><tr><td><strong>Addressable Oncology Population<\/strong><\/td><td>4.2\u202fmillion<\/td><td>18.5\u202fmillion<\/td><\/tr><tr><td><strong>Peak Market Value (2035E)<\/strong><\/td><td>\u00a512\u202fbillion<\/td><td>$8.5\u202fbillion<\/td><\/tr><tr><td><strong>HealZen Revenue Potential<\/strong><\/td><td>\u00a51.8\u202fbillion (Greater China)<\/td><td>$120\u202fmillion (royalties)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Orum Therapeutics<\/strong> \u2013 DAC platform (ORM\u20115029, HER2\u2011targeting, Phase\u202fI)<\/li>\n\n\n\n<li><strong>Tallac Therapeutics<\/strong> \u2013 Antibody\u2011conjugated degraders (pre\u2011clinical)<\/li>\n\n\n\n<li><strong>HealZen<\/strong> \u2013 <strong>First Chinese biotech<\/strong> with <strong>two major TPD partnerships<\/strong> (J&amp;J + undisclosed US partner), validating platform leadership<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Validation:<\/strong> Second major partnership in 12 months establishes HealZen as <strong>global leader in TPD drug discovery<\/strong>, attracting <strong>tier\u2011one pharma interest<\/strong><\/li>\n\n\n\n<li><strong>Revenue Diversification:<\/strong> <strong>Upfront and milestone payments<\/strong> provide non\u2011dilutive funding for proprietary pipeline (BTK degrader, undruggable targets)<\/li>\n\n\n\n<li><strong>Greater China Retention:<\/strong> Maintains <strong>domestic commercial rights<\/strong> for potential blockbuster DAC assets, leveraging <strong>local manufacturing and regulatory expertise<\/strong><\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> HealZen\u2019s <strong>Hangzhou facility<\/strong> (capacity 2,000\u202fL) will produce clinical supply for China trials; partner to supply ex\u2011China<\/li>\n\n\n\n<li><strong>Next Milestone:<\/strong> <strong>IND filing<\/strong> for lead DAC candidate expected <strong>Q4\u202f2026<\/strong>, with <strong>Phase\u202fI initiation<\/strong> in US and China <strong>Q1\u202f2027<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding partnership execution, clinical development timelines, and revenue projections for HealZen\u2019s DAC platform. Actual results may differ due to undisclosed partner\u2019s development priorities, competitive dynamics in TPD, and regulatory approval processes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hangzhou HealZen Therapeutics Co., Ltd. announced a global partnership with an undisclosed American biotechnology company&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,2899,149],"class_list":["post-55498","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-adc-xdc","tag-healzen-therapeutics","tag-johnson-johnson"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>HealZen Inks Global DAC Partnership, Second TPD Deal Following J&amp;J Alliance - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hangzhou HealZen Therapeutics Co., Ltd. announced a global partnership with an undisclosed American biotechnology company for degrader\u2011antibody conjugates (DACs), retaining Greater China rights while securing upfront payments, milestones, royalties, and sublicensing revenue. The transaction marks HealZen\u2019s second overseas licensing deal in targeted protein degradation (TPD), following its BTK degrader agreement with Johnson &amp; Johnson in early\u202f2025.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55498\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HealZen Inks Global DAC Partnership, Second TPD Deal Following J&amp;J Alliance\" \/>\n<meta property=\"og:description\" content=\"Hangzhou HealZen Therapeutics Co., Ltd. announced a global partnership with an undisclosed American biotechnology company for degrader\u2011antibody conjugates (DACs), retaining Greater China rights while securing upfront payments, milestones, royalties, and sublicensing revenue. The transaction marks HealZen\u2019s second overseas licensing deal in targeted protein degradation (TPD), following its BTK degrader agreement with Johnson &amp; Johnson in early\u202f2025.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55498\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-26T12:34:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-26T12:34:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55498#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55498\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HealZen Inks Global DAC Partnership, Second TPD Deal Following J&amp;J Alliance\",\"datePublished\":\"2026-01-26T12:34:29+00:00\",\"dateModified\":\"2026-01-26T12:34:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55498\"},\"wordCount\":433,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"HealZen Therapeutics\",\"Johnson &amp; Johnson\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55498#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55498\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55498\",\"name\":\"HealZen Inks Global DAC Partnership, Second TPD Deal Following J&amp;J Alliance - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-26T12:34:29+00:00\",\"dateModified\":\"2026-01-26T12:34:31+00:00\",\"description\":\"Hangzhou HealZen Therapeutics Co., Ltd. announced a global partnership with an undisclosed American biotechnology company for degrader\u2011antibody conjugates (DACs), retaining Greater China rights while securing upfront payments, milestones, royalties, and sublicensing revenue. The transaction marks HealZen\u2019s second overseas licensing deal in targeted protein degradation (TPD), following its BTK degrader agreement with Johnson & Johnson in early\u202f2025.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55498#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55498\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55498#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HealZen Inks Global DAC Partnership, Second TPD Deal Following J&amp;J Alliance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HealZen Inks Global DAC Partnership, Second TPD Deal Following J&amp;J Alliance - Insight, China&#039;s Pharmaceutical Industry","description":"Hangzhou HealZen Therapeutics Co., Ltd. announced a global partnership with an undisclosed American biotechnology company for degrader\u2011antibody conjugates (DACs), retaining Greater China rights while securing upfront payments, milestones, royalties, and sublicensing revenue. The transaction marks HealZen\u2019s second overseas licensing deal in targeted protein degradation (TPD), following its BTK degrader agreement with Johnson & Johnson in early\u202f2025.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55498","og_locale":"en_US","og_type":"article","og_title":"HealZen Inks Global DAC Partnership, Second TPD Deal Following J&amp;J Alliance","og_description":"Hangzhou HealZen Therapeutics Co., Ltd. announced a global partnership with an undisclosed American biotechnology company for degrader\u2011antibody conjugates (DACs), retaining Greater China rights while securing upfront payments, milestones, royalties, and sublicensing revenue. The transaction marks HealZen\u2019s second overseas licensing deal in targeted protein degradation (TPD), following its BTK degrader agreement with Johnson & Johnson in early\u202f2025.","og_url":"https:\/\/flcube.com\/?p=55498","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-26T12:34:29+00:00","article_modified_time":"2026-01-26T12:34:31+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55498#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55498"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HealZen Inks Global DAC Partnership, Second TPD Deal Following J&amp;J Alliance","datePublished":"2026-01-26T12:34:29+00:00","dateModified":"2026-01-26T12:34:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55498"},"wordCount":433,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","HealZen Therapeutics","Johnson &amp; Johnson"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55498#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55498","url":"https:\/\/flcube.com\/?p=55498","name":"HealZen Inks Global DAC Partnership, Second TPD Deal Following J&amp;J Alliance - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-26T12:34:29+00:00","dateModified":"2026-01-26T12:34:31+00:00","description":"Hangzhou HealZen Therapeutics Co., Ltd. announced a global partnership with an undisclosed American biotechnology company for degrader\u2011antibody conjugates (DACs), retaining Greater China rights while securing upfront payments, milestones, royalties, and sublicensing revenue. The transaction marks HealZen\u2019s second overseas licensing deal in targeted protein degradation (TPD), following its BTK degrader agreement with Johnson & Johnson in early\u202f2025.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55498#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55498"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55498#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HealZen Inks Global DAC Partnership, Second TPD Deal Following J&amp;J Alliance"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55498","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55498"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55498\/revisions"}],"predecessor-version":[{"id":55499,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55498\/revisions\/55499"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55498"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55498"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55498"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}